Dave Schulte is a Senior Vice President and Managing Director and leads McKesson Ventures investing efforts. Previously, he helped grow Kaiser Permanente Ventures from $20M to $400M of assets and managed the investment team.

His investments include: Landmark Health (acquired by General Atlantic), SHYFT Analytics (acquired by Medidata), Komodo Health, Aledade, Infusion Express, Omada Health, Proteus Digital Health, Ingenious Med, MetricStream, Pulmonx, AtheroMed (acquired by Phillips) and Torax Medical (acquired by J&J).

Dave is a member of: the Harvard Kennedy School Health Policy Leadership Council, the Boehringer Ingelheim Digital Health Advisory Council, the Aspen Institute Society of Fellows and the St. John’s University Private Investment Fund.

He is a graduate of St. John’s University and earned a Master of Public Policy from Harvard Kennedy School.

BioPathways is a monthly event series, featuring prominent bioentrepreneurs, biotech executives and biotech investors in a fireside chat.